According to Sauter, feedback from the first customers was overwhelming, with the monitor being used in a much more versatile manner than originally anticipated. In the first quarter after sales commenced, the company had already generated over 50 percent higher sales than had been forecast in the business plan. The first customers were already buying additional devices and the company had succeeded in obtaining a contract from the TERTIANUM Group one of the market leaders for use of the Mobility Monitor in all their residences. Luca Stäger, CEO of the TERTIANUM Group says: "The use of the Mobility Monitor supplements the professional nursing skills of staff at the 16 TERTIANUM residences as well as 5 Perlavita establishments and provides our guests requiring nursing care with individually tailored safety and quality." From the beginning of 2013, the Mobility Monitor will also be distributed in Germany and Sauter reports that discussions are already being held with partners in other countries.
First round of financing successfully completed
Both the idea and the product have convinced investors. Sauter recently completed the first round of financing. Now, he not only has the support of various private investors, but is also backed by institutional investors Lausanne-based pharmaceutical development group Debiopharm, Zürcher Kantonalbank (Cantonal Bank of Zurich) and Empa, the Swiss Federal Laboratories for Materials Science and Technology.
"I am delighted with the excellent investment structure. We now benefit not only from the capital these investors are providing, but also from their expertise and huge networks", comments Sauter. Thierry Mauvernay, Debiopharm Group's Delegate of the Board adds: "The start-up spirit is greatly valued by Debiopharm. We want to foster and sustain it by supporting other entrepreneurs over the long term. compliant concept corresponds to our idea of the medicine for the future, where prevention reduces healthcare costs as well as the suffering of the most fragile patients."
The newly injected capital will enable compliant concept to grow further and expand into other countries.